ReviewToxins2010
Spider-venom peptides as therapeutics.
Review in Toxins, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
134 citing papers in PubMed, 1 synthesis or guideline pooled it, 293 citations in OpenAlex.
- Centipede Venom Peptides Acting on Ion Channels.Toxins · 2020Pooled it
- Total synthesis and structural characterization of a novel protein scaffold from the snail Biomphalaria glabrata.Protein science : a publication of the Protein Society · 2026Article
- Arthropod venom peptides: Pioneering nanotechnology in cancer treatment and drug delivery.Cancer pathogenesis and therapy · 2026Review
- Web of Potentials: Neuroactive Components of Spider Venom and Their Emerging Pharmacologic Applications in Neurologic Diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- A Machine Learning-Enabled Venom Peptide Platform for Rapid Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Peptides derived from exocrine secretions of venomous animals used as traditional Chinese "worm" medicines.Zoological research · 2026Review
- Animal Venom Pharmacological Resources: Exploiting Bioactive Peptides to Target Multi-Drug-Resistant Bacteria.Biochemistry research international · 2026Review
- Discovery of a Novel Anticoagulant Cystine Knot Peptide from Spider Venom Gland Transcriptome.International journal of molecular sciences · 2025Article
- Synthesis of U-theraphotoxin-Pv1a_1, anToxicon: X · 2025Article
- Prospects and challenges of recombinant spider venom enzymes: insights fromFrontiers in bioengineering and biotechnology · 2025Article
- Unveiling Diversity and Function: Venom-Associated Microbes in Two Spiders, Heteropoda venatoria and Chilobrachys guangxiensis.Microbial ecology · 2024Article
- Spider's Silk as a Potential Source of Antibiotics: An Integrative Review.Probiotics and antimicrobial proteins · 2024Review
- Enlightening the toxinological dark matter of spider venom enzymes.npj biodiversity · 2024Article
- Determining the pharmacological potential and biological role of linear pseudoscorpion toxins via functional profiling.iScience · 2024Article
- Shining a Light on Venom-Peptide Receptors: Venom Peptides as Targeted Agents for In Vivo Molecular Imaging.Toxins · 2024Review
- Bee Venom: Composition and Anticancer Properties.Toxins · 2024Review
- Production of recombinant DNA fragmentation factor 40 in fusion to an antimicrobial peptide from spider venom and evaluation of its cytotoxic effects.Research in pharmaceutical sciences · 2024Article
- Spider-Venom Peptides: Structure, Bioactivity, Strategy, and Research Applications.Molecules (Basel, Switzerland) · 2023Review
- The Identification of a Novel Spider Toxin Peptide, Lycotoxin-Pa2a, with Antibacterial and Anti-Inflammatory Activities.Antibiotics (Basel, Switzerland) · 2023Article
- In Silico-Based Design of a Hybrid Peptide with Antimicrobial Activity against Multidrug-ResistantToxins · 2023Article
74 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spiders are the most successful venomous animals and the most abundant terrestrial predators. Their remarkable success is due in large part to their ingenious exploitation of silk and the evolution of pharmacologically complex venoms that ensure rapid subjugation of prey. Most spider venoms are dominated by disulfide-rich peptides that typically have high affinity and specificity for particular subtypes of ion channels and receptors. Spider venoms are conservatively predicted to contain more than 10 million bioactive peptides, making them a valuable resource for drug discovery. Here we review the structure and pharmacology of spider-venom peptides that are being used as leads for the development of therapeutics against a wide range of pathophysiological conditions including cardiovascular disorders, chronic pain, inflammation, and erectile dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.